Search

Displaying results 2791 - 2800 of 4575 in total
  1. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    It was approved by the FDA after being given the status of priority review for on July 7, 2015.

  2. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  3. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). Similar in mechanism to omalizumab, another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its pee...

  4. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  5. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lantibiotics are bacteriocins that are characterized by the presence of a high proportion of unusual amino acids. … Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.

  6. Drug

    Furazolidone

    go.drugbank.com/drugs/DB00614
    InvestigationalVet approved

    A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)

  7. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  8. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  9. Drug

    Von Willebrand factor human

    go.drugbank.com/drugs/DB13133
    ApprovedInvestigational

    It was first approved by the FDA in 2015. … It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the site of blood vessel injury and stabilizing procoagulant factor VIII (FVIII).

  10. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.